| Indicators | Browse All

Oculis Holding AG (OCS)

Healthcare | Biotechnology | Zug, Switzerland | NasdaqGM
13.15 USD -0.48 (-3.522%) ⇩ (July 13, 2026, 4 p.m. EDT)
After hours: 13.15

Short-term:★★☆☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 3:03 a.m. EDT

The investment case for Oculis is currently broken by a confluence of catastrophic operational failure and legal peril. The company recently suffered a 60% share price collapse following the failure of its OCS-01 trial and a subsequent pipeline pivot, which has destroyed the bull thesis. This is compounded by active securities fraud investigations initiated by major law firms, creating a severe overhang where the market is pricing in potential executive liability and further devaluation. Fundamentally, the business is in freefall with negative revenue growth of nearly 27%, massive operating losses, and negative returns on equity and assets. The balance sheet, while technically liquid due to cash holdings, is insufficient to sustain operations without capital raises that will likely dilute shareholders further given the depressed valuation. The options market confirms this pessimism, with traders aggressively buying protection at strikes significantly above the current price. Despite a neutral-to-positive multi-year price trajectory driven by a past rally, the current reality is a deteriorating asset with no clear path to profitability or recovery. Avoid.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.407965
AutoTheta0.408382
AutoETS0.409187
MSTL0.417213

Forecast horizon: 60 days | Selected: AutoARIMA

Forecast Reliability
Score 16%
H-stat 135.32
Ljung-Box p 0.000
Jarque-Bera p 0.013
Excess Kurtosis -1.84
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.143
Revenue per Share 0.02
Market Cap 794,103,104
Forward P/E -6.51
Beta 0.20
Website https://oculis.com

As of July 11, 2026, 3:03 a.m. EDT: Speculators are positioning for a significant downside move, evidenced by heavy put volume and open interest concentrated at strikes 15.0 and 20.0 across multiple expirations. While there is some call activity at the 15.0 strike, the overwhelming majority of open interest sits out-of-the-money on the downside, suggesting a 'bear put spread' or hedging strategy rather than a bullish momentum play.


Info Dump

Attribute Value
52 Week Change -0.24944931
Address1 Bahnhofstrasse 20
All Time High 34.475
All Time Low 6.26
Ask 16.57
Ask Size 2
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 465,200
Average Daily Volume3 Month 738,555
Average Volume 738,555
Average Volume10Days 465,200
Beta 0.202
Bid 12.6
Bid Size 1
Book Value 4.025588
City Zug
Country Switzerland
Crypto Tradeable 0
Currency USD
Current Price 13.15
Current Ratio 5.176
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 13.628
Day Low 12.88
Debt To Equity 1.143
Earnings Timestamp 1,786,046,400
Earnings Timestamp End 1,786,046,400
Earnings Timestamp Start 1,786,046,400
Ebitda -83,243,000
Ebitda Margins 0.0
Enterprise To Ebitda -6.899
Enterprise To Revenue 511.413
Enterprise Value 574,317,184
Eps Current Year -1.76813
Eps Forward -2.0211232
Eps Trailing Twelve Months -2.02
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 19.7399
Fifty Day Average Change -6.589901
Fifty Day Average Change Percent -0.3338366
Fifty Two Week Change Percent -24.944931
Fifty Two Week High 34.475
Fifty Two Week High Change -21.324999
Fifty Two Week High Change Percent -0.6185642
Fifty Two Week Low 10.52
Fifty Two Week Low Change 2.6299992
Fifty Two Week Low Change Percent 0.24999991
Fifty Two Week Range 10.52 - 34.475
Financial Currency CHF
First Trade Date Milliseconds 1,621,344,600,000
Float Shares 52,120,342
Forward Eps -2.0211232
Forward P E -6.5062833
Free Cashflow -27,761,624
Full Exchange Name NasdaqGM
Full Time Employees 60
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -55,237,000
Has Pre Post Market Data 1
Held Percent Insiders 0.035099998
Held Percent Institutions 0.38821998
Implied Shares Outstanding 60,388,073
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,023-03-03
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Long Name Oculis Holding AG
Market us_market
Market Cap 794,103,104
Market State PREPRE
Max Age 86,400
Message Board Id finmb_589165623
Most Recent Quarter 1,774,915,200
Net Income To Common -94,596,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 798,330,325
Number Of Analyst Opinions 11
Open 13.42
Operating Cashflow -62,678,000
Operating Margins -103.961716
Payout Ratio 0.0
Phone 41 41 711 3960
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 13.15
Post Market Time 1,783,973,404
Previous Close 13.63
Price Eps Current Year -7.437236
Price Hint 2
Price To Book 3.2666035
Price To Sales Trailing12 Months 707.1265
Profit Margins 0.0
Quick Ratio 5.098
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.27273
Region US
Regular Market Change -0.48
Regular Market Change Percent -3.52165
Regular Market Day High 13.628
Regular Market Day Low 12.88
Regular Market Day Range 12.88 - 13.628
Regular Market Open 13.42
Regular Market Previous Close 13.63
Regular Market Price 13.15
Regular Market Time 1,783,972,800
Regular Market Volume 300,493
Return On Assets -0.23268999
Return On Equity -0.5266
Revenue Growth -0.267
Revenue Per Share 0.02
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 60,388,073
Shares Percent Shares Out 0.0196
Shares Short 1,183,674
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 651,247
Short Name Oculis Holding AG
Short Percent Of Float 0.0226
Short Ratio 1.01
Source Interval 15
Symbol OCS
Target High Price 50.908688
Target Low Price 22.20762
Target Mean Price 37.21327
Target Median Price 38.393337
Total Cash 222,034,000
Total Cash Per Share 3.677
Total Debt 2,248,000
Total Revenue 1,123,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.02
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 22.519424
Two Hundred Day Average Change -9.369425
Two Hundred Day Average Change Percent -0.4160597
Type Disp Equity
Volume 300,493
Website https://oculis.com
Zip 6,300